Drug Sponsors

SillaJen Biotherapeutics completes name change

Friday, June 20, 2014 01:01 PM

SillaJen, a privately held biotherapeutics company focused on development of targeted oncolytic immunotherapy products for cancer, has completed its name change to SillaJen Biotherapeutics following its acquisition of Jennerex Biotherapeutics.

More... »

WIRB Copernicus Group

Pfizer opens new R&D site in Cambridge, Mass.

Tuesday, June 17, 2014 11:08 AM

Pfizer has announced the opening of a new 280,000-square-foot R&D hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and positions Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations.

More... »

CRF Health eCOA webinar series

Medtronic to acquire Covidien for $42.9 billion

Monday, June 16, 2014 09:43 AM

Medtronic, a global medical technology, services and solutions company, has agreed to acquire Covidien, a global healthcare technology and medical supplies provider, in a cash-and-stock transaction valued at $93.22 per Covidien share, or a total of approximately $42.9 billion, based on Medtronic’s closing stock price of $60.70 per share on June 13. 

More... »

EntreMed stockholders approve name change to CASI Pharmaceuticals

Friday, June 13, 2014 01:13 PM

EntreMed, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of cancer and other diseases, said its annual meeting of stockholders voted in favor of changing the company's corporate name to CASI Pharmaceuticals. The name change will occur June 16, with the rollout of a new web site, www.casipharmaceuticals.com.

More... »

Novo Nordisk to add 6,000 new jobs in Denmark by 2022

Friday, June 13, 2014 01:10 PM

Global healthcare company Novo Nordisk expects to hire 6,000 new employees in Denmark through 2022, half of whom will work within R&D. According to a Novo Nordisk report, the new jobs will have the derived effect of boosting employment by more than 15,000 jobs nationally.

More... »

Cardiovascular Systems plans new corporate headquarters

Friday, June 13, 2014 01:07 PM

Cardiovascular Systems, a medical device company, has plans to build a new corporate headquarters in New Brighton, Minn. The 125,000-square-foot, two-story building will have space for more than 500 employees and contain dedicated R&D, training and education and manufacturing facilities. CSI’s headquarters will be located in the New Brighton Exchange, approximately 10 minutes from downtown Minneapolis.

More... »

TeraDiscoveries changes name to Cloud Pharmaceuticals

Thursday, June 12, 2014 01:38 PM

TeraDiscoveries, a bio-therapeutics company focused on cloud-based drug design and development, has changed its corporate name to Cloud Pharmaceuticals.

More... »

Allergan board unanimously rejects revised Valeant proposal

Wednesday, June 11, 2014 12:54 PM

Allergan’s board of directors has unanimously determined the revised unsolicited proposal by Pershing Square and Valeant Pharmaceuticals International substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan and is not in the best interests of the company and its stockholders.

More... »

Celsion to acquire Egen

Wednesday, June 11, 2014 12:48 PM

Celsion, an oncology drug development company, and Egen, a privately held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, have signed a definitive asset purchase agreement for Celsion to acquire substantially all of Egen’s assets, including its phase Ib DNA-based immunotherapy product candidate Egen-001 and its therapeutic platform technologies, TheraPlas for delivery of DNA and mRNA, TheraSilence for delivery of RNA and RAST for Cell Enabled Expression and Secretion of RNA.

More... »

Merck to acquire Idenix for $3.85 billion

Monday, June 9, 2014 02:01 PM

Merck has agreed to acquire Idenix Pharmaceuticals for $24.50 per share in cash, for a total value of approximately $3.85 billion. The transaction has been approved by the boards of directors of both companies.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs